Details of Disease

General Information of Disease (ID: DISPV68Z)

• Disease Name: Immune System disease
• Disease Class: 4A01-4B41: Immune system disease
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISPV68Z: Immune System disease
• ICD Code:
  ICD-11: ICD-11: 4A01-4B41
  ICD-10: ICD-10: D80-D89

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 16 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Actarit	DMGS3BE	Approved	Small molecular drug	[1]
Bivigam	DMZK7S8	Approved	NA	[1]
Bucillamine	DMRP69M	Approved	Small molecular drug	[1]
Carimune NF	DMFKZ6W	Approved	NA	[1]
Gammaplex	DMOECMG	Approved	NA	[1]
Gusperimus trihydrochloride	DMF334R	Approved	Small molecular drug	[1]
Immune globulin	DMX2OMJ	Approved	NA	[1]
Intragam P	DM5ATQJ	Approved	NA	[1]
Intratect	DMHBDUW	Approved	NA	[1]
Mycophenolate mofetil	DMPQAGE	Approved	Small molecular drug	[2]
Myelopid	DMAH3XB	Approved	NA	[1]
Nanogam	DMAVHUP	Approved	NA	[1]
Pegademase bovine	DMW2TEW	Approved	NA	[1]
Subcuvia	DM501GC	Approved	NA	[1]
Thymopentin	DMMHACE	Approved	Small molecular drug	[1]
UniGAM SD	DM5Q3IZ	Approved	NA	[1]

This Disease is Treated as An Indication in 17 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
NewGam	DMON3EQ	Phase 3	NA	[3]
BMS-936557	DMUTS1W	Phase 2	Antibody	[4]
DNCB	DMDTVYC	Phase 2	Small molecular drug	[5]
Golotimod	DMKZN3A	Phase 2	Small molecular drug	[6]
Leridistim	DM6DL5K	Phase 2	NA	[7]
LOXORIBINE	DMIV9ZE	Phase 2	Small molecular drug	[8]
Thymoctonan	DM4BLJM	Phase 2	Small molecular drug	[9]
TUCARESOL	DMGKQ0K	Phase 2	Small molecular drug	[10]
CAR.CD30 cells	DM6ZXWY	Phase 1/2	CAR T Cell Therapy	[11]
SCID-X stem cell therapy	DMBUMB5	Phase 1/2	NA	[12]
ATLCAR.CD30 cells	DMZI4UX	Phase 1	CAR T Cell Therapy	[13]
ATLCAR.CD30.CCR4 cells	DM3IPSX	Phase 1	CAR T Cell Therapy	[13]
CAR138 T Cells	DMA9M81	Phase 1	CAR T Cell Therapy	[14]
GSK-2018682	DMRU4YV	Phase 1	NA	[15]
IC9-CAR19 cells	DMP1ZF8	Phase 1	CAR T Cell Therapy	[16]
IC9-CAR19 T cells	DMNCBIU	Phase 1	CAR T Cell Therapy	[17]
SSR-125329A	DMG6NI8	Phase 1	NA	[18]

This Disease is Treated as An Indication in 12 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID25553724-Compound-US2011000295210	DMM3QEW	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2011788838110	DMZCO6J	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2011796857710	DMH4DMY	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2011799419010	DMIZ64O	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2011801300410	DMZ96CG	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2011803494010	DMCDHZT	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2011806744710	DMIAV5M	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2012810604610	DM9KAF1	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2012819831110	DMS7RYP	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2012820715110	DMDQ6H7	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2012830453910	DMCUMSV	Patented	Small molecular drug	[19]
PMID25553724-Compound-US2012832440110	DMFCE51	Patented	Small molecular drug	[19]

This Disease is Treated as An Indication in 13 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Betafectin	DMZENON	Discontinued in Phase 3	NA	[20]
Anisperimus	DMJB9J3	Discontinued in Phase 2	Small molecular drug	[21]
CL-246738	DMW1UY5	Discontinued in Phase 2	Small molecular drug	[22]
D-7193	DMO9HWU	Discontinued in Phase 2	NA	[23]
HLA-B7.75-84	DMQ6JOU	Discontinued in Phase 2	Small molecular drug	[24]
N,N`-diacetyl-L-cystine	DMGJLLZ	Discontinued in Phase 2	Small molecular drug	[25]
ONO-4007	DMIZXFJ	Discontinued in Phase 2	Small molecular drug	[26]
TABILAUTIDE	DMA0YYK	Discontinued in Phase 2	Small molecular drug	[27]
CDP-484	DMJTB4E	Discontinued in Phase 1/2	NA	[28]
ANA-975	DMFR3PD	Discontinued in Phase 1	NA	[29]
Discodermolide	DMAR068	Discontinued in Phase 1	Small molecular drug	[30]
OXECLOSPORIN	DM5CO0V	Discontinued in Phase 1	NA	[31]
MRL-953	DM4A92X	Terminated	NA	[32]

This Disease is Treated as An Indication in 28 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AcALY-18	DMLJC1N	Investigative	NA	[33]
Activated adult marrow stromal cells	DMGOQ1F	Investigative	NA	[33]
Anti-CD28	DM5BH7J	Investigative	Antibody	[34]
Anti-IL31	DMK7QK5	Investigative	NA	[33]
AS-1387392	DMQ0502	Investigative	NA	[33]
ATYR-0030	DMGQGW3	Investigative	NA	[33]
BMS-520	DMAY9TM	Investigative	NA	[35]
CGEN-25068	DMRRNPM	Investigative	NA	[33]
CS-0240	DMDBNBS	Investigative	Small molecular drug	[33]
CX-1020	DMYJUQG	Investigative	NA	[33]
CX-1030	DM9C6S6	Investigative	NA	[33]
CX-1040	DMR1VZ0	Investigative	NA	[33]
Ensemblin macrocycle	DMIZ7K5	Investigative	NA	[33]
G009	DMXZGKI	Investigative	NA	[36]
HG-1051	DMM4JCA	Investigative	NA	[37]
HG-1091	DMC8887	Investigative	NA	[33]
HG-1092	DML7KVL	Investigative	NA	[33]
HG-1096	DM9LTD2	Investigative	NA	[33]
HG-1224	DMO1DJS	Investigative	Small molecular drug	[33]
IL-4	DMW1IXD	Investigative	NA	[38]
ImmuMax	DMTPESQ	Investigative	NA	[33]
KI-0903	DMLA6R1	Investigative	NA	[33]
Mam-05.200	DMPEWWS	Investigative	NA	[33]
Napirimus	DMGV3VR	Investigative	Small molecular drug	[33]
PDL-241	DMUU8OC	Investigative	NA	[33]
S-2678	DMF6V73	Investigative	NA	[33]
Sch-036	DMIKJLP	Investigative	NA	[39]
VT-214	DME8TLV	Investigative	NA	[33]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
• [3] ClinicalTrials.gov (NCT01012323) Clinical Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Patients With Primary Immunodeficiency Diseases. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT01466374) Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT00000870) A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT00756951) Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT00004215) Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5018).
• [9] ClinicalTrials.gov (NCT00002435) A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT00343941) Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
• [12] ClinicalTrials.gov (NCT01410019) Gene Therapy for X-linked Severe Combined Immunodeficiency. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
• [14] ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
• [15] ClinicalTrials.gov (NCT01387217) GSK2018682 FTIH in Healthy Volunteers. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT03016377) Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
• [17] ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
• [18] SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties. Eur J Pharmacol. 2002 Dec 5;456(1-3):123-31.
• [19] Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002520)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009259)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000731)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007192)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004203)
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009713)
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003036)
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000836)
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016757)
• [29] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020825)
• [30] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008133)
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002453)
• [32] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002036)
• [33] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2863).
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
• [36] Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res. 2001 May;15(3):245-9.
• [37] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
• [38] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4996).
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).